Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finerenone - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Finerenone - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-94-8862; Firialta; Firialta™; KERENDIA; Kerendia

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies
  • Registered Heart failure
  • Phase III Chronic heart failure; Renal failure; Type 1 diabetes mellitus

Most Recent Events

  • 09 Mar 2026 Polpharma plans a phase III trial for Cardiovascular disorders (In volunteers) in Czech Republic (PO) in March 2026 (CTIS2026-525256-29-00)
  • 02 Feb 2026 Bayer completes a phase III trial in Chronic heart failure in Australia, Malaysia, Greece, the US, Argentina, Belgium, China, Bulgaria, Czech Republic, Hong-Kong, Hungary, Denmark, India, Israel, , Italy, Japan, Mexico, Portugal, Russia, Singapore, South Korea, Spain, Taiwan, UK (PO) (NCT05047263) (EudraCT-2021-000421-27)
  • 30 Jan 2026 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issues a positive recommendation for Finerenone for Heart failure

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top